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Introduction
Chronic kidney disease (CKD) is currently recognized
as a worldwide public health problem.1–4 CKD is best
treated early, before the onset of widespread fibrosis.
This puts a great emphasis on the identification of
patients with early and likely asymptomatic renal dis-
ease. The progression of CKD may be preventable by
the avoidance of nephrotoxic drugs or procedures.
Both the incidence and prevalence of end-stage renal
disease in Taiwan are among the highest in the world.4
The prevalence in Taiwan of CKD stages 3–5 is 6.9%.
However, awareness rates for CKD are relatively low in
Taiwan; they are 8.0% for individuals with stage 3, 25%
for those with stage 4, and 71.4% for those with stage 5.
The lower awareness rates of CKD are closely related to
serum creatinine (Cr) levels. Patients with serum Cr lev-
els higher than the upper normal limit are more likely
to be informed that they have CKD.4,5 Similar reports
have shown that serum Cr levels are frequently normal
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in people with a reduced glomerular filtration rate
(GFR), especially in older and malnourished patients.5–7
Several equations have been developed to estimate
GFR.8–11 The most commonly used is the abbreviated
equation from the Modification of Diet in Renal
Disease (MDRD) study, which was developed by apply-
ing linear regression analysis to data from enrollees in
the MDRD study.8 Calculation of an estimated GFR
(eGFR) is widely accepted as the best method to mea-
sure renal function and define the stage of CKD; yet,
in clinical practice beyond nephrology, it is not widely
utilized.12
Surprisingly, the eGFR equation is routinely used to
identify CKD in people who participate in a self-pay
standard medical screening program in health manage-
ment centers in Taiwan. Since the primary purpose of
such screening programs in health management centers
is to detect illnesses while they are still in the early
stages, the use of eGFR to identify patients with CKD
during health assessment seems strongly justified. The
routine assessment of kidney disease includes blood
urea nitrogen (BUN) and serum Cr levels, urinalysis,
and kidney ultrasound examination. This study aimed
to determine the difference between routine assessment
and the eGFR method in identifying patients with CKD
in health management centers. Study subjects who had
stages 3–5 CKD according to the abbreviated MDRD
(aMDRD) eGFR equation but who had normal results
from routine assessments were classified as the “under-
recognized group”. To identify the risk of renal failure
in study subjects with normal results of routine assess-
ment of kidney disease, episodes of renal failure that had
occurred within 2 years of standard medical screening
were evaluated in all study subjects with stages 3–5
CKD by eGFR.
Methods
All participants in the self-pay standard medical screen-
ing program in the health management center at
Taichung Veterans General Hospital, Taiwan, between
January 2003 and November 2006 were enrolled in the
study. The health management center attracted paying
participants from all over central Taiwan because of its
known quality services. All subjects participated in a
standard medical screening protocol, including a med-
ical interview, comprehensive physical examination,
chest X-ray, resting electrocardiography, echocardio-
graphy, abdominal ultrasound, upper gastrointestinal en-
doscopy, lower gastrointestinal endoscopy, urine and
stool analysis, blood biochemistry, hematology analysis,
thyroid hormone study, and tumor marker screening.
Abnormal BUN was defined as a BUN over the
upper limit of normal (25 mg/dL). Abnormal Cr 
was defined as serum Cr over the upper limit of nor-
mal (1.4 mg/dL). The same cutoff values of serum
Cr were used for males and females. Abnormal uri-
nalysis was defined as the presence of proteinuria
(protein +/– to ++++), hematuria (red blood cells > 2
per high-powered field), pyuria (white blood cells > 2
per high-powered field in males or > 5 per high-
powered field in females), bacteriuria, occult blood,
or glycosuria by spot urine microscopic and chemical
examinations. Abnormal kidney ultrasound was de-
fined as the presence of calcification or stones, cysts,
nodules, hydronephrosis, increased echogenicity,
abnormal kidney size (> 13 cm or < 10 cm) or a single
kidney.
We used the aMDRD equation to estimate GFR as
follows: 186.3× (serum Cr)–1.154 × (age)–0.203 × (0.742
for women).
The classification of CKD was based on clinical prac-
tice guidelines recommended by the Kidney Disease
Outcomes Quality Initiative of the National Kidney
Foundation.8 CKD stages were classified as follows:
patients with a GFR less than 60 mL/min/1.73 m2
were categorized as stages 3–5 CKD; those with a
GFR of 30–59mL/min/1.73m2 were classified as
CKD stage 3; those with a GFR of 15–29mL/
min/1.73m2 as CKD stage 4; and those with a GFR
less than 15mL/min/1.73m2 as CKD stage 5. Stage 3
was further divided into stage 3A (GFR of 45–59mL/
min/1.73m2) and stage 3B (GFR of 30–44 mL/
min/1.73 m2).8,12
Study subjects who had an eGFR less than
60 mL/min/1.73 m2 but with normal results from
routine assessments were classified as “under-recognized
CKD”. Two methods were used to detect episodes of
renal failure in study subjects with stages 3–5 CKD by
eGFR. The first method was a review of the medical
records and the second method was interviews by
phone calls. An episode of renal failure was defined as
renal failure requiring dialysis within 2 years after
standard medical screening.
The prevalence of CKD in this study was mini-
mally affected by missing data. Only 3 participants
were excluded for missing records of medical inter-
views and physical examinations. Another 28 patients
who had undergone regular dialysis or who were kid-
ney transplant recipients were also excluded. All par-
ticipants had provided signed consent for processing
the data generated from medical screening. Ethics
reviews were processed and approved by the Ethics
Committee of Taichung Veterans General Hospital
(IRB TCVGH No: C08052).
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Participants’ characteristics were summarized de-
scriptively (using mean± standard deviation for continu-
ous variables and counts and percentages for categorical
variables). Statistical analysis was performed with SPSS
version 13 (SPSS Inc., Chicago, IL, USA). The cumu-
lative renal survival curve was constructed by Kaplan-
Meier analysis. Intergroup comparisons were presented
with p values by the log-rank test. The multivariate Cox
proportional hazard model was used to analyze the
hazard ratio (HR) and 95% confidence interval (CI)
of stage 3B with abnormal clinical routine assessment
among the other 5 CKD groups. A p value < 0.05 was
considered statistically significant.
Results
The characteristics of all study subjects are summarized
in Table 1. Of the total cohort, 909 subjects (5.7%) had
a history of diabetes mellitus and 3,372 (21.3%) a his-
tory of hypertension; 489 (3.1%) had abnormal serum
Cr levels and 317 (2.0%) had abnormal BUN levels.
Abnormal kidney ultrasound results were found in
2,626 (16.6%), while 3,698 (23.4%) had at least 1 ab-
normal urine analysis result. A total of 1,060 (6.7%)
subjects had proteinuria over 30 mg (1 +) and 664
(4.2%) had trace proteinuria (+/–), 2,521 (15.9%) sub-
jects had hematuria, 3,580 (22.6%) subjects had pyuria,
and 221 (1.4%) subjects had glycosuria. Compared to
males, females had significantly more hematuria (23.1%
vs. 10.9%, p = 0.024) and pyuria (38% vs. 11.8%, 
p < 0.001). Among subjects with abnormal serum Cr
or BUN levels, 139 of 537 subjects (25.9%) had nor-
mal urine analysis results. In total, 28.4% of study
subjects were identified as having a kidney problem
by routine clinical assessment and were referred to
nephrologists.
Using the aMDRD equation to estimate GFR,
1,319 (8.3%) subjects had stage 3A CKD and 188
(1.9%) subjects had stage 3B CKD (Table 2). Another
54 (0.3%) subjects had stage 4 CKD and 32 (0.2%)
subjects had stage 5 CKD. Overall, 1,593 (10.7%)
study subjects including 1,002 (10.8%) males and 591
(9%) females, were diagnosed as stages 3–5 CKD. The
overall prevalence of stages 3–5 CKD among study
subjects older than 60 years was 29.3% (Figure 1). The
prevalence of stages 3–5 CKD increased with age.
Table 2 shows the range, mean, and mode of serum Cr
in all subjects with stages 3–5 CKD. Female subjects
had lower levels of the range, mean, and mode of
serum Cr than males. All 86 patients who were identi-
fied as stage 4 or 5 CKD via the aMDRD equation had
serum Cr levels higher than 1.4 mg/dL, and were
found to have kidney disease via the standard medical
screening program. The serum Cr level of all subjects
with stage 3 CKD was 1.0–2.6 mg/dL. All female
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Table 1. Characteristics of study subjects in the standard medical screening program*
Total Male Female
Study subjects 15,817 (100) 9,264 (58.6) 6,553 (41.4)
Age (yr) 51.5 ± 12.4 (15–90) 51.5 ± 12.5 (16–90) 51.1 ± 12.3 (15–86)
≥ 80 138 (0.9) 114 (1.2) 24 (0.4)
70–79 1,190 (7.5) 748 (8.1) 442 (6.7)
60–69 2,613 (16.5) 1,445 (15.6) 1,168 (17.8)
50–59 4,772 (30.2) 2,824 (30.5) 1,948 (29.7)
40–49 4,580 (29.0) 2,828 (30.5) 1,752 (26.7)
< 40 2,524 (15.9) 1,321 (14.3) 1,203 (18.4)
Stages 3–5 CKD 1,593 (10.1) 1,002 (10.8) 591 (9.0)
Diabetes mellitus 909 (5.7) 602 (6.5) 307 (4.7)
Hypertension 3,372 (21.3) 2,009 (21.7) 1,363 (20.8)
Abnormal serum Cr (> 1.4 mg/dL) 489 (3.1) 329 (3.6) 160 (2.4)
Abnormal BUN (> 25 mg/dL) 317 (2.0) 167 (1.8) 150 (2.3)
Abnormal urinalysis† 3,698 (23.4) 1,133 (12.2) 2,565 (39.1)
Abnormal kidney ultrasound‡ 2,626 (16.6) 1,608 (17.4) 1,018 (15.5)
*Data are presented as n (%) or mean ± standard deviation (range); †abnormal urinalysis is defined as the presence of proteinuria, hematuria, pyuria, bacteri-
uria, occult blood, or glycosuria by spot urine microscopic and chemical examinations; ‡abnormal kidney ultrasound is defined as the presence of calcification
or stones, cysts, nodules, hydronephrosis, increased echogenicity, abnormal kidney size (> 13 cm or < 10 cm), or a single kidney. CKD = chronic kidney disease;
Cr = creatinine; BUN = blood urea nitrogen.
subjects with stage 3A CKD had normal serum Cr
level of 1.0–1.2 mg/dL. Male participants had a higher
percentage of stage 3 CKD, but a lower percentage of
stages 4 and 5 CKD compared to females (Table 3).
Among subjects with stages 3–5 CKD, 921 (57.8%)
subjects (69.7% males, 37.7% females) had normal
urinalysis results. Since all subjects with stages 4 and 5
CKD had abnormal serum Cr levels, we evaluated the
results of routine assessments in subjects with stage 3
CKD. In 188 subjects with stage 3B CKD, 78 (41.5%)
subjects (46.7% males, 32.4% females) had normal
urinalysis results. Of 1,507 subjects with stage 3 CKD
identified by the aMDRD equation, 470 subjects had
abnormal serum Cr levels with or without abnormal
BUN levels, while 734 (48.7%) had normal results for
serum Cr and BUN levels, urinalysis and kidney ultra-
sound (Table 4). These 734 (4.6%) study subjects 
out of the total of 15,817 were then classified as
under-recognized.
All 1,593 study subjects with stages 3–5 CKD
identified by the aMDRD equation were evaluated
via medical records and interviews. Eighteen subjects
were lost at this cross-sectional follow-up. In total, 
32 episodes of renal failure requiring dialysis within 
2 years after standard medical screening were found in
the remaining 1,575 study subjects. Table 5 demon-
strates the episodes of renal failure in all subjects with
stages 3–5 CKD by eGFR. Six (18.8%) subjects with
stage 5 CKD developed renal failure. Two (3.7%)
subjects with stage 4 CKD developed renal failure.
Figure 2 shows the cumulative renal survival of differ-
ent CKD groups. The group of stage 3B with normal
routine clinical assessment had the lowest renal sur-
vival and the group of stage 5 CKD had the second
lowest renal survival. There was no significant differ-
ence in survival between these 2 groups. Compared
with stage 3B with normal routine clinical assessment
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Figure 1. Prevalence of stages 3–5 chronic kidney disease by age
group.
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Table 3. Clinical manifestation of study subjects with normal serum
creatinine levels and stage 3 chronic kidney disease identified by
the abbreviated Modification of Diet in Renal Disease equation
CKD stage
3A* (n) 3B† (n)
Total subjects 1,319 188
Classified as normal by serum Cr, 713 21
BUN, and routine assessment
Subjects with serum Cr > 1.4 mg/dL 295 141
Subjects with serum BUN > 25 mg/dL 101 106
Subjects with abnormal urinalysis 427 20
Subjects with abnormal kidney 302 15
ultrasound
*Glomerular filtration rate of 45–59 mL/min/1.73 m2; †glomerular filtration
rate of 30–44 mL/min/1.73 m2. CKD = chronic kidney disease; Cr = creatinine;
BUN = blood urea nitrogen.
Table 4. Univariate analysis of baseline variables in association with risk of renal failure in 2 years of follow-up (n = 1,575 patients
with available data)
Variable HR 95% CI p
Age (per 10 yr) 1.09 1.05–1.11 < 0.001
Male sex 1.01 0.92–1.09 0.437
Diabetes mellitus 1.39 1.28–1.55 < 0.001
Hypertension 1.27 0.89–1.91 0.209
Serum albumin (g/dL) 0.89 0.79–1.12 0.303
Hemoglobin (g/dL) 1.05 0.94–1.21 0.178
Abnormal urinalysis 1.06 0.94–1.19 0.292
Abnormal kidney ultrasound 0.99 0.95–1.04 0.195
eGFR (mL/min/1.73 m2) 0.82 0.72–0.91 < 0.001
Stage 5 CKD Reference
Stage 4 CKD 0.86 0.71–0.94 0.005
Stage 3B* CKD with normal routine clinical assessment 1.06 0.98–1.15 0.263
Stage 3B* CKD with abnormal routine clinical assessment 0.71 0.25–0.93 0.001
Stage 3A† CKD with normal routine clinical assessment 0.55 0.41–0.69 < 0.001
Stage 3A† CKD with abnormal routine clinical assessment 0.42 0.33–0.58 < 0.001
*Glomerular filtration rate of 30–44 mL/min/1.73 m2; †glomerular filtration rate of 45–59 mL/min/1.73 m2. HR = hazard ratio; CI = confidence interval;
eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease.
and stage 5 CKD, the other 4 groups had significantly
higher renal survival (p < 0.05) and the between-
group comparisons were not significant.
Univariate logistic regression showed that being
older (HR, 1.09; 95% CI, 1.05–1.11), having dia-
betes mellitus (HR, 1.39; 95% CI, 1.28–1.55), and
lower baseline GFR (HR, 0.82; 95% CI, 0.72–0.94)
were associated with a higher risk of renal failure
within 2 years (Table 4). By age-adjusted multivariate
Cox proportional survival analysis, having diabetes
mellitus (HR, 1.44; 95% CI, 1.21–1.66) and lower base-
line GFR (HR, 0.82; 95% CI, 0.72–0.94) remained
independent predictors of renal failure within 2 years.
Stage 5 CKD and stage 3B CKD with normal routine
clinical assessment had a similar risk of renal failure
and this risk was significantly higher than that for the
other CKD groups (Table 5).
Discussion
In the past 2 decades, the kidney disease screening
program has changed in Japan and many coun-
tries.4,13 The program started with urinalysis and
measurements of serum Cr and estimation of GFR by
equation were added later. Currently, formulaic esti-
mations of GFR are widely used by nephrologists, but
these estimations have many pitfalls. Although eGFR
reporting could promote identification of more cases
of CKD, it is also possible that attention and
resources could be directed towards patients falsely
identified as having CKD or with early CKD.
Application of eGFR without adjustment for the
effects of racial disparity, age and sex may also result
in over-diagnosis of CKD.14,15 Although increasing
the rate of patient referral to nephrologists on the
basis of eGFR could increase costs and use of medical
resources, nephrologists obtain better blood pressure
control and slower progression of renal function than
non-nephrologists.16,17 Moreover, the purpose of
self-pay standard medical screening programs in
health management centers is to evaluate how healthy
a person is and help minimize the barriers to health
care. The routine health assessment tools for identify-
ing kidney disease in most management centers in
Taiwan are serum Cr and BUN levels, urinalysis, and
kidney ultrasound. The eGFR equation is not included.
In our cohort, 28.4% of study subjects were identified
as having a kidney problem by the above routine assess-
ment tools and were referred to nephrologists. How-
ever, only a small percentage of subjects had abnormal
results for serum Cr levels (3.1%) and BUN levels
(2.0%), and proteinuria over 30mg (6.7%). The percen-
tage of proteinuria in our study is similar to a previous
report from a nationally representative survey in
Taiwan.4 Although 22.6% of subjects had pyuria and
15.9% had hematuria, it is not surprising that female
subjects had significantly higher percentages of hema-
turia and pyuria than male subjects. The use of urinalysis
is not sufficient to screen for kidney disease. A signifi-
cant proportion of subjects with either stages 3–5 CKD
or abnormal serum Cr/BUN levels had normal uri-
nalysis results. On the other hand, many subjects with
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Table 5. Age-adjusted multivariate Cox proportional model for the effect of baseline variables on the risk of renal failure (n = 1,575
patients with available data)
Variable HR 95% CI p
Diabetes mellitus 1.44 1.21–1.66 0.005
eGFR (mL/min/1.73 m2) 0.86 0.67–0.98 0.001
Stage 5 CKD Reference
Stage 4 CKD 0.89 0.61–0.96 0.01
Stage 3B* CKD with normal routine clinical assessment 1.02 0.94–1.18 0.346
Stage 3B* CKD with abnormal routine clinical assessment 0.77 0.45–0.93 0.01
Stage 3A† CKD with normal routine clinical assessment 0.59 0.46–0.73 < 0.001
Stage 3A† CKD with abnormal routine clinical assessment 0.33 0.23–0.64 < 0.001
*Glomerular filtration rate of 30–44 mL/min/1.73 m2; †glomerular filtration rate of 45–59 mL/min/1.73 m2. HR = hazard ratio; CI = confidence interval;
eGFR = estimated glomerular filtration rate; CKD = chronic kidney disease.
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Figure 2. Two-year cumulative renal survival in study subjects with an estimated glomerular filtration rate < 60 mL/min/1.73 m2
by Kaplan-Meier analysis. The p values for comparison between groups are presented by log-rank test. CKD = chronic kidney disease.
stages 3–5 CKD or abnormal serum Cr/BUN levels
had normal kidney ultrasound results. Some kidney
ultrasound findings, such as renal stones or cysts, may
not directly predict a risk of developing renal failure.
Using the aMDRD eGFR equation, we found that
10.1% of study subjects had stages 3–5 CKD. We found
that 734 (48.7%) subjects with stage 3 CKD had nor-
mal results for serum Cr and BUN, urinalysis and kid-
ney ultrasound. Moreover, significant episodes of renal
failure requiring dialysis were found among the 4.6%
of subjects who were classified as under-recognized.
Taiwan has the largest end-stage renal disease popula-
tion in the world, and therefore, early identification
of CKD (e.g. via the application of the aMDRD eGFR
equation) is very important.4 A nationally represen-
tative survey from Taiwan in 2002 showed that the
prevalence of stages 3–5 CKD in Taiwan was 6.9%.4
However, the awareness rates for CKD in Taiwan were
very low, being only 8% in stage 3 CKD. The low
awareness rate was closely related to serum Cr levels.
Subjects with serum Cr levels greater than 1.6 mg/dL
(> 141 μmol/L) were more likely to be informed that
they have kidney disease.4 Another large-scale prospec-
tive cohort study based on 462,293 adults in Taiwan
also reported a high prevalence of CKD and its associ-
ated all-cause mortality.5 It also reported a significant
lack of awareness of CKD among the study subjects in
a standard medical screening program run by a private
health management institution in Taiwan.
We found that all subjects with stages 4 and 5 CKD
identified via the aMDRD equation had abnormal
serum Cr levels and were identified as having kidney
disease. For subjects with stage 4 or 5 CKD, many non-
nephrologists may underestimate the disease status of
CKD and fail to prevent the episode of acute or chronic
renal disease. The low-limit values of serum Cr in sub-
jects with stage 3 CKD for males and females were
1.3 mg/dL and 1.0 mg/dL, respectively. Both values
overlapped the upper limit of normal for serum Cr
level, which is 1.4 mg/dL. This finding challenges the
traditional upper normal limit value for serum Cr. Fur-
ther studies by separate gold standards such as iothala-
mate clearance or inulin clearance may help to adjust
the normal range for serum Cr in Taiwanese.
Even if the routine clinical assessment tools for kid-
ney disease are combined, a significant percentage of
under-recognized CKD and a risk of renal failure were
still reported in the current study. Episodes of renal
failure within 2 years after standard medical screening
may not be the best way to evaluate the accuracy of
the eGFR equation or the routine assessment in health
management centers. Although we failed to evaluate
changes in serum Cr or eGFR in this large cohort,
episodes of renal failure vary in different stages of CKD.
Subjects with stage 3 CKD and normal routine clini-
cal assessments had a higher risk of developing renal
failure requiring dialysis compared with subjects with
at least 1 abnormal routine clinical assessment. In par-
ticular, subjects with stage 3B CKD and normal routine
clinical assessments may have the highest risk of devel-
oping renal failure requiring dialysis within 2 years.
One possible explanation is that most clinicians may
neglect the risk of renal injury induced by nephrotoxic
drugs or procedures in patients with stage 3 CKD
when they have had a normal renal function survey by
serum Cr and BUN, urinalysis, and kidney ultrasound.
There is growing evidence to suggest that patients
with stage 3B have a higher risk of cardiovascular dis-
ease and rapid renal function progression compared
with stage 3A patients.18–22
Some limitations of this study should be noted.
First, the relatively very small number of subjects with
stage 3B CKD with normal routine clinical assessment
may have had an impact on episodes of renal failure.
Second, the definition of renal failure requiring dialy-
sis was based on episodes of both acute and chronic
renal failure requiring dialysis within 2 years after stan-
dard medical screening by review of medical records
and interviews by phone. Potential errors from the
phone interviews may also have limited the generaliz-
ability of the results.
The eGFR equation is not widely used in most
clinical practices beyond nephrology in Taiwan,
including most standard medical screening programs
of health management centers. Our findings provide
strong evidence for using the aMDRD eGFR equation
as a routine assessment for CKD. In agreement with
increasingly more international organizations, we have
established an automatic eGFR reporting system by
clinical laboratory in our hospital whenever serum Cr
is measured to facilitate early recognition of CKD and
to reduce the potential risk of nephrotoxic drugs or
procedures.23–25
There remains a lack of clarity in the definition of
abnormal routine clinical assessment and its clinical sig-
nificance in CKD classification for stages 3, 3A and 3B.
In particular, abnormal laboratory findings are mainly
due to non-renal problems, such as hematuria due to
extra-renal origin, pyuria due to lower urinary tract in-
fection and occult blood due to pigmenturia (hemo-
globin or myoglobin), as well as renal cysts, stones,
nodules or calcification, and change in kidney size with
interference with kidney function. However, we failed
to further reanalyze these factors in stage 3 CKD.
Accordingly, patients with stage 3 CKD were arbi-
trarily classified into only 2 groups (with or without
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normal routine clinical assessment), and this could
have led to overestimating patient numbers in the 2
subgroups, in terms of stages 3A (n = 606) and 3B
(n = 167) CKD with abnormal routine clinical assess-
ment. Therefore, the crude rate of renal failure neces-
sary for dialysis could have been exaggerated in stages
3A (1.7%) and 3B (20%) CKD with normal routine
clinical assessment. We also failed to reclassify the
subgroups in stages 3A and 3B CKD patients and
reanalyze the crude rate of renal failure progression.
In conclusion, in the current large-cohort study,
we found an apparent disagreement in identifying
stage 3 CKD between routine clinical assessment tools
and the aMDRD eGFR equation in a standard med-
ical screening program. The significantly higher risk
of renal failure in under-recognized stage 3B CKD
suggests the value of using the eGFR equation in a
health management institution and general clinical
practice, especially in countries with a high prevalence
of CKD such as Taiwan.
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